Ingesting Versus Inhaling Could Save 60,000 Lives a Year

Technology for healthier drug molecule delivery

“Everybody knows that smoking is not healthy. Our technology allows for the delivery of drug molecules like cannabinoids or nicotine through ingesting means. Things that you swallow and that could be a pill, it could be a syrup, could be a cup of coffee. If we are able to help change the consumption habits of even 1 percent of the global marketplace who smoke we could save 60,000 lives a year.” – Chris Bunka, CEO of Lexaria Bioscience

Lexaria Bioscience Corp. (CSE:LXX; OTCQX:LXRP) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.

For more information on Lexaria Bioscience Corp. (LXX:CSE, LXRP:OTCQX) please fill out the form below.

Request Investor Kit

Name*

Email*

*Required.